Informed consent to study purpose in randomized clinical trials of antibiotics, 1991 through 2011

JAMA Internal Medicine

Volumn 177, Issue 10, 2017, Pages 1452-1459

  Doshi, Peter ^a   Hur, Peter ^a   Jones, Mark ^b   Albarmawi, Husam ^a   Jefferson, Tom ^c   Morgan, Daniel J ^d,e   Spears, Patricia A ^f,g   Powers, John H ^h  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e Centre for Disease Dynamics Economics and Policy   (United States)

^f NORTH CAROLINA STATE UNIVERSITY   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; ANTIBIOTIC AGENT; AZTREONAM; COLISTIN; DAPTOMYCIN; DORIPENEM; ERTAPENEM; FIDAXOMICIN; RETAPAMULIN; TELAVANCIN; TELITHROMYCIN; TIGECYCLINE; TOBRAMYCIN; TROVAFLOXACIN; TURVEL; ANTIINFECTIVE AGENT;

ARTICLE; CLINICAL PROTOCOL; CROSS-SECTIONAL STUDY; DRUG EFFICACY; EUROPEAN MEDICINES AGENCY; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; PROCEDURES; RETROSPECTIVE STUDY; UTILIZATION;

ANTI-BACTERIAL AGENTS; CONSENT FORMS; CROSS-SECTIONAL STUDIES; HUMANS; INFORMED CONSENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 85031030258     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2017.3820     Document Type: Article

References (33)

1. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects; 2013. https://www.wma.net/policies-post/wma-declaration-of-helsinki -ethical-principles-for-medical-research-involving -human-subjects/. Accessed July 1, 2017.
2. National Commission for the Protection of Human Subjects. Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. US Government Printing Office; 1978. https://videocast.nih.gov/pdf/ohrp_belmont_report.pdf. Accessed July 1, 2017.
3. Department of Health and Human Services. Protection of human subjects. 2009;45 CFR 46. https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html. Accessed July 1, 2017.
4. Food and Drug Administration. Non-Inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry; 2016. https://www.fda.gov/downloads/Drugs/.../Guidances/UCM202140.pdf. Accessed July 1, 2017.
5. Food and Drug Administration. Draft guidance for industry on non-inferiority clinical trials; availability. Fed Regist. 2010;75(39):9228-9229.
6. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006;145(1):62-69.
7. Fleming TR. Current issues in non-inferiority trials. Stat Med. 2008;27(3):317-332.
8. Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB. Fundamentals of Clinical Trials. New York, NY: Springer; 2015.
9. Government Accountability Office. New Drug Approval: FDA’s Consideration of Evidence from Certain Clinical Trials (GAO-10-798); 2010. http://www.gao.gov/new.items/d10798.pdf. Accessed July 1, 2017.
10. Committee on Strategies for Responsible Sharing of Clinical Trial Data, Board on Health Sciences Policy, Institute of Medicine. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Washington, DC: National Academies Press; 2015.
11. Persaud N, Doshi P. North American regulatory agencies can and should make clinical trial data publicly available. CMAJ. 2016;188(2):96-97.
12. Doshi P, Hur P, Jones M, et al. Dataset for "Informed Consent to Study Purpose in Randomized Clinical Trials of Antibiotics, 1991 Through 2011". doi:10.5281/zenodo.825517
13. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. http://handbook.cochrane.org. Accessed July 1, 2017.
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Choice of Control Group and Related Issues in Clinical Trials (ICH E10); 2000. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4 /E10_Guideline.pdf. Accessed July 1, 2017.
15. Food and Drug Administration. Points to Consider: Clinical Development and Labeling of Anti-Infective Drug Products; 1992. https://www.fda.gov/downloads/drugs /guidancecomplianceregulatoryinformation /guidances/ucm070975.pdf. Accessed July 1, 2017.
16. Food and Drug Administration. Justification of Non-Inferiority Margin for the Treatment of Complicated Skin and Skin Structure Infections; 2002. https://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4394b1-01-FDA.pdf. Accessed July 1, 2017.
17. Department of Health and Human Services. Adequate and Well-Controlled Studies. 2010;21 CFR 314.126. https://www.gpo.gov/fdsys/granule/CFR-2010-title21-vol5/CFR-2010-title21-vol5-sec314 -126. Accessed July 1, 2017.
18. Nuremberg Code. Trials of War Criminals Before the Nuremberg Military Tribunals Under Control Council Law No. 10. vol 2; 1949:181-182. https://www.loc.gov/rr/frd/Military_Law/pdf/NT_war-criminals_Vol-II.pdf. Accessed July 1, 2017.
19. Djulbegovic B, Clarke M. Ethical issues in the reporting of clinical trials. JAMA. 2001;286(13): 1577-1578.
20. Pinto VF. Non-inferiority clinical trials: concepts and issues. J Vasc Bras. 2010;9(3):145-151.
21. Powers JH. Noninferiority and equivalence trials: deciphering ‘similarity’ of medical interventions. Stat Med. 2008;27(3):343-352.
22. Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA. 2014;311(4):368-377.
23. Li Y, He Y, Sheng Y, et al. Systematic evaluation of non-inferiority and equivalence randomized trials of anti-infective drugs. Expert Rev Anti Infect Ther. 2013;11(12):1377-1389.
24. Djulbegovic B, Clarke M. Scientific and ethical issues in equivalence trials. JAMA. 2001;285(9): 1206-1208.
25. Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in ClinicalTrials.gov—the final rule. N Engl J Med. 2016;375(20):1998-2004.
26. Casadevall A, Pirofski L-A. Microbiology: ditch the term pathogen. Nature. 2014;516(7530):165-166.
27. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012; 54(12):1699-1709.
28. Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. https://www.fda.gov/Drugs/DrugSafety/ucm369580.htm. Accessed December 1, 2016.
29. Food and Drug Administration. Safety Alerts for Human Medical Products - Doribax (doripenem): Drug Safety Communication - Risk When Used to Treat Pneumonia on Ventilated Patients. 2014. https://wayback.archive-it.org/7993/20170112164151/http:/www.fda.gov/Safety /MedWatch/SafetyInformation /SafetyAlertsforHumanMedicalProducts /ucm388328.htm. Accessed July 1, 2017.
30. Committee for Medicinal Products for Human Use; Efficacy Working Party; Committee for Release for Consultation. Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin. Stat Med. 2006;25(10): 1628-1638.
31. Clinton WJ, Gore A. Reinventing Regulation of Drugs and Medical Devices. Washington, DC: National Performance Review; 1995.
32. Schultz WB; Food and Drug Administration. Statement regarding the demonstrations of effectiveness of human drug products and devices. Fed Regist. 1995;60(147):39181-39182.
33. Knottnerus BJ, Geerlings SE, Moll van Charante EP, ter Riet G. Women with symptoms of uncomplicated urinary tract infection are often willing to delay antibiotic treatment: a prospective cohort study. BMC Fam Pract. 2013;14:71. doi:10.1186/1471-2296-14-71